Gynazole 1 (butoconazole nitrate)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Butoconazole nitrate, an imidazole derivative, is a synthetic azole antifungal agent.
USES: This medication is used to treat vaginal yeast infections. Butoconazole reduces vaginal burning, itching, and discharge that may occur with this condition. This medication is an azole antifungal.
It works by stopping the growth of yeast (fungus) that causes the infection. If you have fever, chills, flu-like symptoms, stomach/abdominal pain, or a bad-smelling vaginal discharge, do not use this medication. Contact your doctor right away because these may be signs of a more serious infection.
Generic name: butoconazole nitrate
Pronunciation: (BUE-toe-KON-a-zole NYE-trate)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Gynazole 1
Indications
The following indications are listed for Gynazole 1:
- Vulvovaginal Candidiasis
Also known as: Vaginal Candidiasis, Vulvovaginal Candidosis, Vulvovaginal Moniliasis.
Dosing
No dosing information is available for this tab.
Butoconazole nitrate is administered intravaginally as a 2% cream. Butoconazole nitrate vaginal cream is for intravaginal administration only and should not be administered orally; contact with the eyes should be avoided.
Butoconazole nitrate vaginal cream should be used for self-medication of recurrent vulvovaginal candidiasis only in otherwise healthy, nonpregnant women previously diagnosed by a clinician.
Patients should be instructed how to use the vaginal applicator and should be given a copy of the instructions provided by the manufacturer.
Butoconazole nitrate vaginal cream contains a mineral oil base that may weaken rubber or latex products, including condoms or vaginal contraceptive diaphragms, and use of such products within 72 hours following treatment with intravaginal butoconazole is not recommended.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Reproduction studies in pregnant rats receiving 6 mg/kg of butoconazole nitrate intravaginally daily (3-7 times the usual human intravaginal dose) during the period of fetal organogenesis have shown an increased fetal resorption rate and decreased litter size, but evidence of teratogenicity was not observed. Adverse reproductive effects have not been reported following oral administration of butoconazole nitrate to pregnant rats at dosages up to 50 mg/kg daily (5 times the usual human dosage based on mg/m2) throughout organogenesis. Orally administered dosages of 100, 300, or 750 mg/kg daily (10, 30, or 75 times, respectively, the usual human dosage) in pregnant rats have resulted in fetal malformations (e.g., abdominal wall defects, cleft palate), but maternal stress was evident at these higher dosages and may have been a contributing factor. Teratogenic effects were not observed in rabbits receiving oral butoconazole nitrate doses associated with maternal stress (i.e., 150 mg/kg; 24 times the usual human dosage based on mg/m2). Like other imidazole antifungal agents, butoconazole has been associated with dystocia in rats when therapy with the drug was extended through parturition; however, this effect has not been observed in rabbits.
There are no adequate and controlled studies to date with butoconazole nitrate in pregnant women during the first trimester. The manufacturer states that intravaginal butoconazole should be used during pregnancy only if the potential benefits justifies the possible risks to the fetus. The CDC and others state that a 7-day regimen of an intravaginal azole antifungal can be used, if necessary, for the treatment of vulvovaginal candidiasis in pregnant women.
Since it is not known whether butoconazole is distributed into milk, the drug should be used with caution in nursing women.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.